ESCAPE - Evaluation of Prostate Specific Membrane Antigen Positron Emission Tomography-Computed Tomography in Active Surveillance for Prostate CancEr
This study will be assessing the ability of PSMA-PET CT to determine the absence of clinically significant prostate cancer in patients on active surveillance (AS) with low risk and favorable intermediate-risk prostate cancer.
• Males aged ≥ 18.
• Histologically confirmed low or favorable intermediate risk prostate cancer per NCCN guidelines. (Note: Grade Group 2 must have 20% or less involvement in every core and no presence of cribiform or intraductal carcinoma).
• PSA \< 20 ng/ml.
• Ability to undergo yearly PSMA-PET CT.
• Ability to undergo yearly prostate mpMRI.
• Ability to undergo transrectal or transperineal template and fusion prostate biopsy.
• Ability to complete HRQOL surveys (EPIC, IPSS, IIEF-5).
• Willingness to undergo yearly prostate biopsies.